Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics

Xiaojing Chu, Yu Zhang, Sijin Cheng

2022, 34(6): 543-553. doi: 10.21147/j.issn.1000-9604.2022.06.01

Burden of liver cancer: From epidemiology to prevention

Qianru Li, Maomao Cao, Lin Lei, Fan Yang, He Li, Xinxin Yan, Siyi He, Shaoli Zhang, Yi Teng, Changfa Xia, Wanqing Chen

2022, 34(6): 554-566. doi: 10.21147/j.issn.1000-9604.2022.06.02

Postoperative functional evaluation of gastrectomy for gastric cancer

Eiji Nomura

2022, 34(6): 567-574. doi: 10.21147/j.issn.1000-9604.2022.06.03

Advances in gastric cancer research will light the way to control this cancer

Paulo Pimentel de Assumpção, Rommel Rodrigues Burbano

2022, 34(6): 575-578. doi: 10.21147/j.issn.1000-9604.2022.06.04

Evolution of laparoscopic gastrectomy for cancer in the East and West

Eider Talavera-Urquijo, Bas P. L. Wijnhoven

2022, 34(6): 579-586. doi: 10.21147/j.issn.1000-9604.2022.06.05

Advances in surgical techniques for gastric cancer: Indocyanine green and near-infrared fluorescence imaging. Is it ready for prime time?

Erica Sakamoto, Adriana Vaz Safatle-Ribeiro, Ulysses Ribeiro Jr

2022, 34(6): 587-591. doi: 10.21147/j.issn.1000-9604.2022.06.06

Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China

Binghe Xu, Huiping Li, Zefei Jiang, Lin Gu, Jinhai Tang, Hui Xie, Yueyin Pan, Yunjiang Liu, Shude Cui, Xiaojia Wang, Li Cai, Yiqiong Zhang, Huadong Zhao, Zhimin Shao

2022, 34(6): 592-600. doi: 10.21147/j.issn.1000-9604.2022.06.07

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera^®) in patients with CD20-positive B-cell non-Hodgkin lymphoma

Xiaohong Han, Mingzhi Zhang, Huaqing Wang, Qingyuan Zhang, Wei Li, Miaowang Hao, Yuhuan Gao, Jie Jin, Hanyun Ren, Yun Tang, Xiaonan Hong, Xiaoyan Ke, Hang Su, Lin Gui, Jianmin Luo, Liangzhi Xie, Wenlin Gai, Yuankai Shi

2022, 34(6): 601-611. doi: 10.21147/j.issn.1000-9604.2022.06.08

Prognostic implications of tumor-infiltrating lymphocytes in association with programmed cell death ligand 1 expression in remnant gastric cancer

Marina Alessandra Pereira, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Leonardo Cardili, Rafael Dyer Rodrigues de Moraes, Renan Ribeiro E Ribeiro, Venancio Avancini Ferreira Alves, Bruno Zilberstein, Evandro Sobroza de Mello, Ulysses Ribeiro Jr

2022, 34(6): 612-622. doi: 10.21147/j.issn.1000-9604.2022.06.09

Chinese quality control indices for standardized diagnosis and treatment of gastric cancer (2022 edition)

Shen Li, Fei Shan, Xiaotian Zhang, Yongheng Li, Yu Sun, Lei Tang, Qi Wu, Wenjing Yang, Jincheng Yang, Yu An, Ming Deng, Jiafu Ji

2022, 34(6): 623-632. doi: 10.21147/j.issn.1000-9604.2022.06.10

Comments on National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version)

Yuan Feng, Nan Wu

2022, 34(6): 633-634. doi: 10.21147/j.issn.1000-9604.2022.06.11

Comments on National guidelines for diagnosis and treatment of melanoma 2022 in China (English version)

Jiaran Zhang, Lu Si, Jun Guo

2022, 34(6): 635-636. doi: 10.21147/j.issn.1000-9604.2022.06.12

Comments on National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version)

Kemin Jin, Baocai Xing

2022, 34(6): 637-643. doi: 10.21147/j.issn.1000-9604.2022.06.13

Corrigendum to Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)

2022, 34(6): 644-644. doi: 10.21147/j.issn.1000-9604.2022.06.14